Top

Published in:

Open Access 01-03-2007 | Topic Paper

Overdiagnosis and overtreatment of early detected prostate cancer

Authors: C. H. Bangma, S. Roemeling, F. H. Schröder

Published in: World Journal of Urology | Issue 1/2007

Abstract

Early detection of prostate cancer is associated with the diagnosis of a considerable proportion of cancers that are indolent, and that will hardly ever become symptomatic during lifetime. Such overdiagnosis should be avoided in all forms of screening because of potential adverse psychological and somatic side effects. The main threat of overdiagnosis is overtreatment of indolent disease. Men with prostate cancer that is likely to be indolent may be offered active surveillance. Evaluation of active surveillance studies and validation of new biological parameters for risk assessment are expected.

de Koning HJ, Auvinen A, Berenguer Sanchez A et al (2002) Large-scale randomized prostate cancer screening trials: program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 97(2):237–244PubMedCrossRef

Lowe JB, Ball J, Lynch BM et al (2004) Acceptability and feasibility of a community-based screening programme for melanoma in Australia. Health Promot Int 19(4):437–444PubMedCrossRef

Van Iersel CA, de Koning HJ, Draisma G et al (2006) Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer (in press)

Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS (2006). Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355(17):1763–1771PubMedCrossRef

O’Brien B, Nichaman L, Browne JE, Levin DL, Prorok PC, Gohagan JK (2000) Prostate, lung, colorectal and ovarian cancer screening trial project team. coordination and management of a large multicenter screening trial: the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 21(Suppl 6):310S–328SPubMedCrossRef

Catalona WJ, Smith DS, Ratliff TL et al (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324(17):1156–1161PubMedCrossRef

Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108PubMedCrossRef

Sakr WA, Grignon DJ, Crissman JD et al (1994) High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases. In Vivo 8(3):439–443PubMed

Nadler RB, Loeb S, Roehl KA, Antenor JA, Eggener S, Catalona WJ (2005) Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. J Urol 174(6):2154–2157PubMedCrossRef

10.

Aus G, Abbou CC, Bolla M et al (2005) EAU guidelines on prostate cancer. Eur Urol 48(4):546–551PubMedCrossRef

11.

Welch HG, Schwartz LM, Woloshin S (2005) Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst 97(15):1132–1137PubMedCrossRef

12.

Kopec JA, Goel V, Bunting PS et al (2005) Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study. J Urol 174(2):495–499; discussion 499

13.

Concato J, Wells CK, Horwitz RI et al (2006) The effectiveness of screening for prostate cancer: a nested case-control study. Arch Intern Med 166(1):38–43PubMedCrossRef

14.

Weinmann S, Richert-Boe K, Glass AG, Weiss NS (2004) Prostate cancer screening and mortality: a case-control study (United States). Cancer Causes Control 15(2):133–138PubMedCrossRef

15.

Postma R, van Leenders AG, Roobol MJ, Schroder FH, van der Kwast TH (2006) Tumor features in the control and screening arm of a randomized trial of prostate cancer. Eur Urol 50(1):70–5 Epub 2005 Dec 19

16.

Gosselaar C, Roobol MJ, Schroder FH (2005) Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant? BJU Int 95(2):231–7 Review

17.

Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271(5):368–374PubMedCrossRef

18.

Auvin A, Maattanen L, Stenman UH et al (2002) Lead-time in prostate cancer screening (Finland). Cancer Causes Control 13(3):279–285PubMedCrossRef

19.

Draisma G, Boer R, Otto SJ et al (2003) Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst 95(12):868–878PubMed

20.

Rietbergen JB, Hoedemaeker RF, Kruger AE, Kirkels WJ, Schroder FH (1999) The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. J Urol 161(4):1192–1198PubMedCrossRef

21.

Bill-Axelson A, Holmberg L, Ruutu M et al (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352(19):1977–1984PubMedCrossRef

22.

Draisma G, Postma R, Schroder FH, van der Kwast TH, de Koning HJ (2006) Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer 119(10):2366–2371PubMedCrossRef

23.

Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293(17):2095–2101PubMedCrossRef

24.

Johansson JE, Andren O, Andersson SO et al (2004) Natural history of early, localized prostate cancer. JAMA 291(22):2713–2719PubMedCrossRef

25.

Klotz L (2006) Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol 7(5):355–362PubMed

26.

Bangma CH, Rietbergen JB, Kranse R, Blijenberg BG, Petterson K, Schroder FH (1997) The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol 157(6):2191–2196PubMedCrossRef

27.

Raaijmakers R, de Vries SH, Blijenberg BG, Wildhagen MF, Postma R, Bangma CH, Darte C, Schröder FH (2007) HK2 and free PSA, a powerful prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4–10 ng/mL. Eur Urol (submitted)

28.

Yurdakul G, Bangma CH, Blijenberg BG, van Zelst BD, Wildhagen MF, van der Kwast TH, Schroder FH (2002) Different PSA assays lead to detection of prostate cancers with identical histological features. Eur Urol 42(2):154–158PubMedCrossRef

29.

Roobol MJ, Roobol DW, Schroder FH (2005) Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology 65(2):343–346PubMedCrossRef

30.

Crawford ED, Pinsky PF, Chia D, Kramer BS, Fagerstrom RM, Andriole G, Reding D, Gelmann EP, Levin DL, Gohagan JK (2006) Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. J Urol 175(4):1199–2000CrossRef

31.

Sokoloff MH, Brendler CB (2000) Radical retropubic prostatectomy. Principles and Practice of Oncology Updates 14:1

32.

Stanford JL, Feng Z, Hamilton AS et al (2000) Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 283(3):354–360PubMedCrossRef

33.

Benoit RM, Naslund MJ, Cohen JK (2000) Complications after radical retropubic prostatectomy in the medicare population. Urology 56(1):116–120PubMedCrossRef

34.

Hamilton AS, Stanford JL, Gilliland FD et al (2001) Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the prostate cancer outcomes study. J Clin Oncol 19(9):2517–2526PubMed

35.

Gelblum DY, Potters L (2000) Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 48(1):119–124PubMedCrossRef

36.

Kleinberg L, Wallner K, Roy J et al (1994) Treatment-related symptoms during the first year following transperineal 125I prostate implantation. Int J Radiat Oncol Biol Phys 28(4):985–990PubMed

37.

Theodorescu D, Gillenwater JY, Koutrouvelis PG (2000) Prostatourethral-rectal fistula after prostate brachytherapy. Cancer 89(10):2085–2091PubMedCrossRef

38.

Klotz LH (2005) Active surveillance for good risk prostate cancer: rationale, method, and results. Can J Urol 12(Suppl 2):21–24PubMed

39.

Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT (1996) Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 156(3):1059–1063PubMedCrossRef

40.

Kattan MW, Eastham JA, Wheeler TM et al (2003) Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170(5):1792–1797PubMedCrossRef

41.

Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schröder FH (2007). Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 177:107–112PubMedCrossRef

42.

Van Gils MPMQ, Stenman UH, Schalken JA, Schröder FH, Luider TM, Lilja H, Bjartell A, Hemdy FC, Petterson KSI, Bischoff R, Takalo H, Nilsson O, Mulders PFA, Bangma CH (2005) Innovations in serum and urine markers in prostate cancer.Current European research in the P-Mark project. Eur Urol 48:1031–1041PubMedCrossRef

Title: Overdiagnosis and overtreatment of early detected prostate cancer
Authors: C. H. Bangma
S. Roemeling
F. H. Schröder
Publication date: 01-03-2007
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 1/2007
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-007-0145-z

At a glance: The STEP trials

Springer Medicine

Overdiagnosis and overtreatment of early detected prostate cancer

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2007

Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters

Gender discrepancies in the diagnosis of renal cortical tumors

Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2–10 ng/ml in 4,480 men

Percutaneous radiotherapy for low-risk prostate cancer: options for 2007

Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma

Treatment of localized prostate cancer